Goldman Remains Cautious on Myriad (MYGN) Following Q2 Results; Moves PT to $22

February 5, 2014 2:46 PM

Goldman Sachs bumps its price target on Myriad Genetics (Nasdaq: MYGN) from $20 to $22, while remaining Neutral following FQ214 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found